We are live on
!
Find out more
ED
Exane Derivatives Portfolio holdings
AUM
$174M
1-Year Est. Return
7.84%
This Fund
S&P 500
This Quarter
Est. Return
-2.43%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$80.8M
(-14%)
Cap. Flow
-$34.9M
Cap. Flow
% of AUM
-6.99%
Top 10 Holdings %
Top 10 Hldgs %
34.04%
Holding
671
New
64
Increased
221
Reduced
213
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PepsiCo
PEP
|
+$9.36M |
| 2 |
ArcelorMittal
MT
|
+$8.22M |
| 3 |
AT&T
T
|
+$7.11M |
| 4 |
AB InBev
BUD
|
+$5.34M |
| 5 |
BCE
BCE
|
+$4.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares China Large-Cap ETF
FXI
|
+$43.3M |
| 2 |
UBS Group
UBS
|
+$34.3M |
| 3 |
RSX
VanEck Russia ETF
RSX
|
+$17.1M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$12.4M |
| 5 |
Stellantis
STLA
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.51% |
| 2 | Communication Services | 11.94% |
| 3 | Materials | 10.5% |
| 4 | Consumer Discretionary | 9.71% |
| 5 | Financials | 9.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Lam Research
LRCX
$339B
| $122K | 0.02% |
6,230
-121,890
| -95% | -$2.41M |
|
277
ICU Medical
ICUI
$3.9B
| $120K | 0.02% |
487
+23
| +5% | +$5.41K |
|
|
UN
278
DELISTED
Unilever NV New York Registry Shares
UN
| $120K | 0.02% |
+2,143
| New | +$118K |
|
279
Fortuna Silver Mines
FSM
$3.44B
| $119K | 0.02% |
23,000
| – | – |
|
280
Royal Caribbean
RCL
$66.7B
| $118K | 0.02% |
1,017
+999
| +5,550% | +$126K |
|
281
Progressive
PGR
$129B
| $117K | 0.02% |
1,934
+94
| +5% | +$5.37K |
|
282
Morgan Stanley
MS
$324B
| $115K | 0.02% |
2,189
+210
| +11% | +$11.6K |
|
283
Regenxbio
RGNX
$524M
| $114K | 0.02% |
+4,000
| New | +$116K |
|
|
PXD
284
DELISTED
Pioneer Natural Resource Co.
PXD
| $114K | 0.02% |
681
-269
| -28% | -$47.4K |
|
285
Vertex Pharmaceuticals
VRTX
$130B
| $113K | 0.02% |
709
+708
| +70,800% | +$116K |
|
286
Danaher
DHR
$147B
| $113K | 0.02% |
1,308
-96
| -7% | -$8.4K |
|
287
Salesforce
CRM
$210B
| $113K | 0.02% |
998
-14,369
| -94% | -$1.65M |
|
|
FLIR
288
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $112K | 0.02% |
2,264
+112
| +5% | +$5.58K |
|
289
Ecolab
ECL
$77B
| $111K | 0.02% |
821
+17
| +2% | +$2.29K |
|
290
Autodesk
ADSK
$47.3B
| $111K | 0.02% |
878
-1,021
| -54% | -$122K |
|
291
BioMarin Pharmaceuticals
BMRN
$12.5B
| $108K | 0.02% |
1,363
+1,331
| +4,159% | +$114K |
|
292
Fastenal
FAST
$56.7B
| $107K | 0.02% |
8,048
-20
| -0.2% | -$275 |
|
293
KLA
KLAC
$220B
| $107K | 0.02% |
9,960
+9,580
| +2,521% | +$107K |
|
294
UnitedHealth
UNH
$337B
| $106K | 0.02% |
487
+24
| +5% | +$5.48K |
|
295
Weyerhaeuser
WY
$16.1B
| $105K | 0.02% |
2,995
+147
| +5% | +$5.19K |
|
296
Suncor Energy
SU
$84.1B
| $103K | 0.02% |
3,002
| – | – |
|
|
SAGE
297
DELISTED
Sage Therapeutics
SAGE
| $103K | 0.02% |
+662
| New | +$112K |
|
|
SHPG
298
PUT
DELISTED
Shire pic
SHPG
| $102K | 0.02% |
20
-40
| -67% | -$5.51K |
|
|
KERX
299
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $101K | 0.02% |
+25,506
| New | +$119K |
|
300
Invesco Pharmaceuticals ETF
PJP
$541M
| $99.7K | 0.02% |
1,617
-1,431
| -47% | -$94.2K |
|
Similar funds
PC
TWMP
LPWM
ACM
HWIS
LWM
EW
GDWAM
Exane Derivatives's Q1 2018 Portfolio in Review
As of Q1 2018, Exane Derivatives held 671 positions worth $500M, down 14% from $581M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Exane Derivatives withdrew a net $34.9M in Q1 2018, closing 46 positions and reducing 213 holdings. Its most notable exit was UBS Group, an estimated $34.3M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 24% of assets, down from 39% a quarter earlier, followed by Communication Services and Materials.
Against the trend, Exane Derivatives opened a new position in AB InBev worth $5.29M.
- Exane Derivatives's largest Q1 2018 buy was AB InBev: 48,192 shares worth $5.29M.
- Exane Derivatives added most to PepsiCo in Q1 2018, an estimated $9.36M increase.
- Exane Derivatives's biggest Q1 2018 reduction was iShares China Large-Cap ETF, cutting an estimated $43.3M.
- Exane Derivatives fully exited UBS Group in Q1 2018, selling an estimated $34.3M.
- Exane Derivatives's ten largest holdings make up 34% of its $500M portfolio in Q1 2018.
- Exane Derivatives opened 64 new positions and closed 46 in Q1 2018.
- Exane Derivatives's portfolio value fell 14% quarter-over-quarter to $500M.
Based on Exane Derivatives's 13F filing for Q1 2018, filed 30 Apr 2018.